SymBio Pharma Reports January Exercise

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 2, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

SymBio Pharma Reports January Exercise Status of Warrants

Source disclosure: February 02, 2026 SymBio Pharmaceuticals Limited [4582.T] TOKYO, Feb 02 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582.T) reported the exercise status of its 58th and 65th warrants for January 2026. The 58th warrant was issued to CVI Investments, Inc. On June 01, 2022, while the 65th warrant was issued to EVO FUND on August 12, 2025. In January, 5,600 of the 65th warrants were exercised, representing a 0.01% ratio of total outstanding warrants. No exerci